MARKET

IMRN

IMRN

Immuron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.050
-0.071
-3.33%
Closed 16:00 06/01 EDT
OPEN
2.000
PREV CLOSE
2.121
HIGH
2.070
LOW
2.000
VOLUME
3.41K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.550
MARKET CAP
9.08M
P/E (TTM)
-2.5268
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMRN stock price target is 6.19 with a high estimate of 6.19 and a low estimate of 6.19.

EPS

IMRN News

More
Immuron Board Relinquish Cash Payment of Fees
GlobeNewswire · 04/28 11:00
Mid-Morning Market Update: Markets Open Lower; Coca-Cola Tops Q1 Estimates
Following the market opening Tuesday, the Dow traded down 1.8% to 23224.37 while the NASDAQ fell 2.04% to 8386.31. The S&P also fell, dropping 1.89% to 2,769.81.
Benzinga · 04/21 14:23
Mid-Afternoon Market Update: Dow Falls Over 400 Points; NovaBay Pharmaceuticals Shares Jump
Toward the end of trading Monday, the Dow traded down 1.79% to 23807.82 while the NASDAQ fell 0.49% to 8607.34. The S&P also fell, dropping 1.28% to 2837.73.
Benzinga · 04/20 18:31
Mid-Day Market Update: Crude Oil Plunges 45%; Cyclacel Pharmaceuticals Shares Jump
Midway through trading Monday, the Dow traded down 0.71% to 24,070.23 while the NASDAQ rose 0.35% to 8,680.06. The S&P also fell, dropping 0.28% to 2,866.43.
Benzinga · 04/20 16:04
Mid-Morning Market Update: Markets Open Lower ; Halliburton Earnings Top Views
Following the market opening Monday, the Dow traded down 1.41% to 23901.55 while the NASDAQ fell 0.48% to 8608.89. The S&P also fell, dropping 1.03% to 2844.82.
Benzinga · 04/20 14:52
Immuron up 36% on Travelan sales ramp
Seeking Alpha - Article · 04/20 14:25
Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
GlobeNewswire · 04/20 11:00
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.)
Benzinga · 04/07 11:57

Industry

Pharmaceuticals
-1.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About IMRN

Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.
More

Webull offers kinds of Immuron Limited stock information, including NASDAQ:IMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRN stock news, and many more online research tools to help you make informed decisions.